How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. LaCasce discusses data that emerged in 2016 for novel immunotherapy approaches in Hodgkin lymphoma and non-Hodgkin lymphoma.
Dr. LaCasce looks at clinical trials that compare nivolumab and pembrolizumab and demonstrate the efficacy of targeting PD-1 in classical Hodgkin Lymphoma.
Dr. LaCasce provides an overview of pediatric-type nodal follicular lymphoma.
Dr. LaCasce looks at understanding the use of checkpoint inhibitors to redirect the immune system to eliminate RS cells as an attractive therapeutic approach to classical Hodgkin lymphoma.
Dr. LaCasce discusses the use of BLC2 as an effective therapy for patients with CLL, including those with poor risk features.
Dr. LaCasce explores therapies used to target lymphoma involving the central nervous system (CNS) and primary testicular lymphoma, unique subtypes of DLBCL.
Drs. Johnson and LaCasce look at several trials that used interim positron emission tomography (PET) scanning to determine efficacy of treatment of Hodgkin lymphoma (HL).
Dr. LaCasce discusses a new prognostic model in follicular lymphoma that incorporates both genetic and clinical factors.
Dr. LaCasce discusses a study that evaluates CAR T-cell therapy as a promising novel approach in patients with refractory aggressive B-cell lymphoma.
Dr. LaCasce looks at the advantages that come with monitoring circulating tumor DNA in patients with DLBCL, to determine treatment, such as accuracy, cost, and safety.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology